Neal D Tolley

US Patent:

20100297621, Nov 25, 2010

Filed:

Jun 20, 2008

Appl. No.:

12/452333

Inventors:

Andrew S. Weyrich - Salt Lake City UT, US
Hansjorg Schwertz - Salt Lake City UT, US
Guy Zimmerman - Salt Lake City UT, US
Neal Tolley - Salt Lake City UT, US

Assignee:

UNIVERSITY OF UTAH RESEARCH FOUNDATION - Salt Lake City UT

International Classification:

C12Q 1/68

US Classification:

435 6

Abstract:

The invention relates to materials and procedures for identifying or using tissue factor (TF) pre-mRNA splicing, CIk 1 activity or TF-dependent coagulation in platelet cells for the diagnosis, prognosis, or prediction of a disease or disorder associated with disordered coagulation. Since activated platelets splice pre-mRNAs to generate inflammatory and thrombotic mediators that contribute to diseases such as sepsis and septic shock, (TF) pre-mRNA splicing in platelets is an indicator of inflammatory and thrombotic disease states. TF pre-mRNA splicing in platelets is correlated with sepsis, increased age (≧65), APACHE II score, and bacteremia. Thus, TF mRNA expression patterns in platelets may be used for the diagnosis, prognosis, or prediction of a disease or disorder associated with disordered coagulation, for example, patients that are at a higher risk for severe sepsis, organ failure, and death.

US Patent:

20090042869, Feb 12, 2009

Filed:

Jun 20, 2008

Appl. No.:

12/143645

Inventors:

Andrew S. Weyrich - Salt Lake City UT, US
Hansjorg Schwertz - Salt Lake City UT, US
Guy Zimmerman - Salt Lake City UT, US
Neal Tolley - Salt Lake City UT, US

Assignee:

UNIVERSITY OF UTAH RESEARCH FOUNDATION - Salt Lake City UT

International Classification:

A61K 31/54
C12Q 1/68
C40B 30/06
G01N 33/00
A61P 7/00
C40B 30/08
C12Q 1/02

US Classification:

5142242, 435 6, 506 10, 436 86, 506 11, 435 29

Abstract:

The invention relates to therapeutic target recognition, development, and validation of a compound capable of directly or indirectly modulating TF pre-mRNA splicing in a platelet cell and the use of a platelet TF pre-mRNA splicing modulator for the treatment of a subject suffering from, or thought to be suffering from, disordered coagulation.